Insight Molecular Diagnostics Sets $1.75 Share Price For Financing Its Transplant-Test Research

The offering is expected to bring approximately $15 million before fees and expenses for working capital and other corporate spending.

Share
Insight Molecular Diagnostics Sets $1.75 Share Price For Financing Its Transplant-Test Research

Insight Molecular Diagnostics, which develops molecular tests to monitor transplanted-organ rejection, priced new shares at $1.75 each Tuesday in an offering expected to generate approximately $15 million before fees and expenses. The company described the financing in an 8-K filed Wednesday and intends to use the money for corporate spending, including transplantation research.

New Shares And Nearly Paid Warrants

The company is selling 8,296,429 common shares, alongside pre-funded warrants covering up to 275,000 shares. All the securities are being sold by Insight Molecular Diagnostics.

The warrants let investors pay almost the entire share price upfront: $1.7499 for each warrant, followed by $0.0001 per share when exercised. Buyers can exercise them upon issuance, and they remain available until fully exercised.

Lake Street Capital Markets, the offering's sole managing underwriter, received a 30-day option to buy up to 1,285,714 additional shares at the offering price, less underwriting discounts and commissions.

Funding The Transplant-Test Business

Management plans to put the proceeds remaining after expenses toward working capital and other corporate needs, including transplantation research and development.

Insight Molecular Diagnostics performs its Medicare-reimbursed GraftAssureCore test at its laboratory in Franklin, Tennessee. It sells GraftAssureIQ kits for research and is developing GraftAssureDx kits for clinical use by local laboratories.

The company targets hospitals, transplant centers and laboratories. Its laboratory-services business develops tests and performs clinical testing for life sciences and biotechnology companies. Insight Molecular Diagnostics also develops cancer-related tests and maintains research laboratories in Nashville, Tennessee, and Göttingen, Germany.

A 90-Day Limit On Further Sales

Insight Molecular Diagnostics agreed to a 90-day restriction on selling stock or filing for additional stock offerings, subject to exceptions. Warrant exercise is limited when a holder and related parties would exceed 4.99% ownership, or 9.99% if the holder elects that threshold.

The company launched the offering Monday, cautioning that market and other conditions could affect its completion, timing, size and terms. The financing uses a shelf registration—an existing registration for securities offerings—that became effective on August 7, 2024.

The company expects the offering to close on or about Wednesday; the approximately $15 million remains expected gross proceeds, before underwriting fees and other expenses.

Sources

More on Insight Molecular Diagnostics

All Insight Molecular Diagnostics (IMDX) coverage →